
    
      Three part study:

      Part A - 4 week treatment period evaluating PLN-74809 or matching placebo

      Part B - 12 week treatment period evaluating PLN-74809 or matching placebo

      Part C - 12 week treatment period evaluating up to two higher PLN-74809 dose cohorts or
      matching placebo
    
  